BioSpace News Archive

The specialized resource offers patients with rare mutations or fusions in non-small cell lung cancer (NSCLC) and their caregivers access to treatment information, informative webinars, the latest scientific news, and a supportive community.

Elandas, Inc. announced it has merged with long-standing partner AccessSync, LLC, a US-based strategic market access execution services provider.

Palleon and Henlius to co-develop Bifunctional HER2-Sialidase and a second bifunctional sialidase to be jointly designed.

Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application for its MALT1 inhibitor, SGR-1505.

XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced it has achieved enrollment of target number of subjects in the Phase 2 portion of its ongoing Phase 1/2 clinical trial (EXACT) for refractory angina.

Dunad appoints new CEO as company establishes U.S. operations, continues to expand its platform based on novel insights into covalent chemistry and build its internal drug discovery programs.

On May 31, 2022, Medisca, a global supplier of pharmaceutical compounding products, acquired DIFFUSIMAX® and DIFFUSIMAX®10 liposomal bases (pluronic lecithin organogel or PLO gel), products used for preparing compounded topical formulations, as well as all intellectual property assets of Maxima Pharmaceuticals.

CareDx, Inc. today announced its participation and presenting sponsorship for the 2022 Donate Life Transplant Games taking place July 29 to August 3, 2022, in San Diego, California.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Jacks Lee to its Board of Directors.

Titan Medical Inc. announced that multiple disruptions have resulted in an updated Investigational Device Exemption submission timeline for the Enos™ robotic single access surgery system.